*|MC:SUBJECT|*
up-to-date with a click!
Update  - Issue February, 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Key publications

Other

  1. Sahebkar A, Simental-Mendia LE, Watts GF et al. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med 2017; 15:22. http://www.ncbi.nlm.nih.gov/pubmed/?term=28153024
  2. Fitzpatrick T, Perrier L, Tricco AC et al. Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data. BMJ Open 2017; 7:e013770. http://www.ncbi.nlm.nih.gov/pubmed/?term=28213601
  3. Santos L, Davel AP, Almeida TI et al. Soy milk versus simvastatin for preventing atherosclerosis and left ventricle remodeling in LDL receptor knockout mice. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 2017; 50:e5854. http://www.ncbi.nlm.nih.gov/pubmed/?term=28225891
  4. Roever L. Erratum to "Pitavastatin vs Pravastatin in Reduction of Remnant Lipoprotein Cholesterol in Patients with Dyslipidemias" Clin Ther. 2016;39:1250--1251. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28237671
  5. Nguyen T, Karl M, Santini A. Red Yeast Rice. Foods (Basel, Switzerland) 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28257063

Add on treatments

  1. E D, E S, G D et al. Effect of ezetimibe on plasma adipokines: A Systematic review and meta-analysis. Br J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28166606
  2. Leiter LA, Zamorano JL, Bujas-Bobanovic M et al. Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28206704
  3. Sirenko Y, Radchenko G. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2017; 24:85-93. http://www.ncbi.nlm.nih.gov/pubmed/?term=28150140
  4. Bischoff-Ferrari HA, Fischer K, Orav EJ et al. Statin Use and 25-Hydroxyvitamin D Blood Level Response to Vitamin D Treatment of Older Adults. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240766
  5. Liu X, Li J, Schild SE et al. Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. Journal of cancer therapy 2017; 8:73-85. http://www.ncbi.nlm.nih.gov/pubmed/?term=28239505
  6. Fraunberger P, Grone E, Grone HJ et al. Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. Journal of inflammation (London, England) 2017; 14:3. http://www.ncbi.nlm.nih.gov/pubmed/?term=28167864
  7. Lee JB, Kim GS, Cho HN. Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy. J Stroke 2017; 19:109-110. http://www.ncbi.nlm.nih.gov/pubmed/?term=28178405
  8. Mozetic V, Freitas CG, Riera R. Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review. JMIR research protocols 2017; 6:e30. http://www.ncbi.nlm.nih.gov/pubmed/?term=28228373
  9. Zhao Y, Peng R, Zhao W et al. Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease. Medicine (Baltimore) 2017; 96:e6104. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207527
  10. Liu Z, Hao H, Yin C et al. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28177908
  11. Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Therapeutic advances in chronic disease 2017; 8:4-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28203346
  12. Tarantino N, Santoro F, De Gennaro L et al. Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag 2017; 13:29-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=28243111

Adherence

  1. Gulayin P, Irazola V, Lozada A et al. Educational intervention to improve effectiveness in treatment and control of patients with high cardiovascular risk in low-resource settings in Argentina: study protocol of a cluster randomised controlled trial. BMJ Open 2017; 7:e014420. http://www.ncbi.nlm.nih.gov/pubmed/?term=28143840
  2. Krumme AA, Sanfelix-Gimeno G, Franklin JM et al. Can purchasing information be used to predict adherence to cardiovascular medications? An analysis of linked retail pharmacy and insurance claims data. BMJ Open 2016; 6:e011015. http://www.ncbi.nlm.nih.gov/pubmed/?term=28186924
  3. Nord JW, Jr., Berry A, Stults B et al. Evaluation of the Effectiveness of a Patient-Centered Educational Mailer Designed to Improve Statin Adherence: A Pragmatic Trial. EGEMS (Washington, DC) 2016; 4:1256. http://www.ncbi.nlm.nih.gov/pubmed/?term=28203610
  4. Munkhaugen J, Sverre E, Otterstad JE et al. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol 2017:2047487317693134. http://www.ncbi.nlm.nih.gov/pubmed/?term=28196429
  5. Wallert J, Lissaker C, Madison G et al. Young adulthood cognitive ability predicts statin adherence in middle-aged men after first myocardial infarction: A Swedish National Registry study. Eur J Prev Cardiol 2017:2047487317693951. http://www.ncbi.nlm.nih.gov/pubmed/?term=28195516
  6. Protty MB, Lacey A, Hayes J, Freeman P. Statins for secondary prevention: clinical use in patients with acute coronary syndrome in Wales. Future cardiology 2017; 13:137-141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28185473
  7. Grover A, Rehan HS, Gupta LK, Yadav M. Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients. Indian Heart J 2017; 69:6-10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28228309
  8. Amin K, Farley JF, Maciejewski ML, Domino ME. Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence. Journal of managed care & specialty pharmacy 2017; 23:337-345. http://www.ncbi.nlm.nih.gov/pubmed/?term=28230447
  9. Lee CJ, Choi S, Cheon DH et al. Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. Lipids Health Dis 2017; 16:49. http://www.ncbi.nlm.nih.gov/pubmed/?term=28245873

Atherosclerosis & Imaging

  1. Kadohira T, Mintz GS, Souza CF et al. Impact of chronic statin therapy on clinical presentation and underlying lesion morphology in patients undergoing percutaneous intervention: an ADAPT-DES IVUS substudy. Coronary artery disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240675
  2. Chhatriwalla AK, Rader DJ. Intracoronary Imaging, Reverse Cholesterol Transport, and Transcriptomics: Precision Medicine in CAD? J Am Coll Cardiol 2017; 69:641-643. http://www.ncbi.nlm.nih.gov/pubmed/?term=28183507
  3. Kataoka Y, Andrews J, Puri R et al. Lipid Lowering Therapy to Modify Plaque Microstructures. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28239070
  4. Brinjikji W, Lehman VT, Kallmes DF et al. The effects of statin therapy on carotid plaque composition and volume: A systematic review and meta-analysis. Journal of neuroradiology. Journal de neuroradiologie 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28187866

Atorvastatin/Rosuvastatin

  1. Panes O, Gonzalez C, Hidalgo P et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2016; 257:164-171. http://www.ncbi.nlm.nih.gov/pubmed/?term=28142075
  2. Kim HS, Lee H, Lee SH et al. Use of Moderate-Intensity Statins for Low-Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28165667
  3. Liang J, Yin K, Cao X et al. Attenuation of Low Ambient Temperature-Induced Myocardial Hypertrophy by Atorvastatin via Promoting Bcl-2 Expression. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2017; 41:286-295. http://www.ncbi.nlm.nih.gov/pubmed/?term=28214881
  4. Koslik HJ, Meskimen AH, Golomb BA. Physicians' Experiences as Patients with Statin Side Effects: A Case Series. Drug safety - case reports 2017; 4:3. http://www.ncbi.nlm.nih.gov/pubmed/?term=28217821
  5. Sirenko Y, Radchenko G. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2017; 24:85-93. http://www.ncbi.nlm.nih.gov/pubmed/?term=28150140
  6. Pinho-Ribeiro V, Melo AC, Kennedy-Feitosa E et al. Atorvastatin and Simvastatin Promoted Mouse Lung Repair After Cigarette Smoke-Induced Emphysema. Inflammation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28251446
  7. Sreter KB, Barisic B, Popovic-Grle S. Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28257284
  8. Dong B, Singh AB, Shende VR, Liu J. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters. International journal of molecular medicine 2017; 39:749-756. http://www.ncbi.nlm.nih.gov/pubmed/?term=28204827
  9. Wei L, Chen JS, Lin HT et al. Atorvastatin from target screening attenuates endothelial cell tube formation and migration by regulating urokinase receptor-related signaling pathway and F/G actin. Journal of the Chinese Medical Association : JCMA 2017; 80:86-95. http://www.ncbi.nlm.nih.gov/pubmed/?term=28159489
  10. Jeong YJ, Kim H, Baik SJ et al. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea. Journal of clinical pharmacy and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28251662
  11. Kapoor S. Rosuvastatin and Its Evolving Role as a Vascular Remodeling and Antiproliferative Agent in Different Systemic Malignancies. J Pharmacol Exp Ther 2017; 360:434. http://www.ncbi.nlm.nih.gov/pubmed/?term=28188271
  12. Lai SW, Liao KF, Lin CL et al. Statins use and female lung cancer risk in Taiwan. The Libyan journal of medicine 2012; 7:20123. http://www.ncbi.nlm.nih.gov/pubmed/?term=28136089
  13. Lee CJ, Choi S, Cheon DH et al. Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. Lipids Health Dis 2017; 16:49. http://www.ncbi.nlm.nih.gov/pubmed/?term=28245873
  14. Zhao Y, Peng R, Zhao W et al. Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease. Medicine (Baltimore) 2017; 96:e6104. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207527
  15. Oliveira KA, Dal-Cim T, Lopes FG et al. Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28181188
  16. Kang SY, Lee SB, Kim HJ et al. Autophagic modulation by rosuvastatin prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson's disease. Neurosci Lett 2017; 642:20-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=28137648
  17. Prajapati SK, Garabadu D, Krishnamurthy S. Coenzyme Q10 Prevents Mitochondrial Dysfunction and Facilitates Pharmacological Activity of Atorvastatin in 6-OHDA Induced Dopaminergic Toxicity in Rats. Neurotox Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28130746
  18. Liu Z, Hao H, Yin C et al. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28177908
  19. Sana T, Aslam B, Aslam N et al. Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. Pak J Pharm Sci 2016; 29:2321-2326. http://www.ncbi.nlm.nih.gov/pubmed/?term=28167473
  20. Park J, Kwon OS, Cho SY et al. Chronic administration of atorvastatin could partially ameliorate erectile function in streptozotocin-induced diabetic rats. PLoS One 2017; 12:e0172751. http://www.ncbi.nlm.nih.gov/pubmed/?term=28245261
  21. Reichert K, Pereira do Carmo HR, Galluce Torina A et al. Correction: Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism. PLoS One 2017; 12:e0172453. http://www.ncbi.nlm.nih.gov/pubmed/?term=28196119
  22. Ye Z, Lu H, Su Q et al. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis. PLoS One 2017; 12:e0171682. http://www.ncbi.nlm.nih.gov/pubmed/?term=28231287
  23. Oztas M, Ugurlu S, Aydin O. Atorvastatin-induced dermatomyositis. Rheumatology international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28238074
  24. Luo Y, Chen Y, Ma H et al. Enhancing the biocatalytic manufacture of the key intermediate of atorvastatin by focused directed evolution of halohydrin dehalogenase. Scientific reports 2017; 7:42064. http://www.ncbi.nlm.nih.gov/pubmed/?term=28165015
  25. Ahsan MN, Prasad Verma PR. Solidified self nano-emulsifying drug delivery system of rosuvastatin calcium to treat diet-induced hyperlipidemia in rat: in vitro and in vivo evaluations. Therapeutic delivery 2017; 8:125-136. http://www.ncbi.nlm.nih.gov/pubmed/?term=28145826
  26. El-Ashmawy NE, Khedr EG, El-Bahrawy HA, Al-Tantawy SM. Chemopreventive effect of omega-3 polyunsaturated fatty acids and atorvastatin in rats with bladder cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017; 39:1010428317692254. http://www.ncbi.nlm.nih.gov/pubmed/?term=28218036
  27. Zhang Y, Wei DD, Yuan RR et al. [Effects of ApoE gene polymorphism on the efficacy of atorvastatin in the treatment of hyperlipidemia]. Zhonghua yi xue za zhi 2017; 97:291-294. http://www.ncbi.nlm.nih.gov/pubmed/?term=28162160

Basic science

  1. Elkadi S, Elsamaligy S, Al-Suwayeh S, Mahmoud H. The Development of Self-nanoemulsifying Liquisolid Tablets to Improve the Dissolution of Simvastatin. AAPS PharmSciTech 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28236269
  2. Khanfar M, Al-Nimry S. Stabilization and Amorphization of Lovastatin Using Different Types of Silica. AAPS PharmSciTech 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28127721
  3. Coban N, Gulec C, Ozsait Selcuk B, Erginel-Unaltuna N. Role of simvastatin and RORalpha activity in the macrophage apoptotic pathway. Anatol J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28179616
  4. Andrade-Pavon D, Cuevas-Hernandez RI, Trujillo-Ferrara JG et al. Recombinant 3-Hydroxy 3-Methyl Glutaryl-CoA Reductase from Candida glabrata (Rec-CgHMGR) Obtained by Heterologous Expression, as a Novel Therapeutic Target Model for Testing Synthetic Drugs. Appl Biochem Biotechnol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28138930
  5. Zhou HX, Gao LH, Meng LL et al. Preventive and therapeutic effect of simvastatin on secondary inflammatory damage of rats with cerebral hemorrhage. Asian Pac J Trop Med 2017; 10:152-156. http://www.ncbi.nlm.nih.gov/pubmed/?term=28237480
  6. Ouweneel AB, van der Sluis RJ, Nahon JE et al. Simvastatin treatment aggravates the glucocorticoid insufficiency associated with hypocholesterolemia in mice. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28242047
  7. Han W, Li J, Tang H, Sun L. Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level. Biochem Biophys Res Commun 2017; 484:396-402. http://www.ncbi.nlm.nih.gov/pubmed/?term=28131832
  8. Hirooka S, Ueno M, Fukuda S et al. Effects of Simvastatin on Alveolar Regeneration and Its Relationship to Exposure in Mice with Dexamethasone-Induced Emphysema. Biological & pharmaceutical bulletin 2017; 40:155-160. http://www.ncbi.nlm.nih.gov/pubmed/?term=28154254
  9. Cui X, Long C, Zhu J, Tian J. Protective Effects of Fluvastatin on Reproductive Function in Obese Male Rats Induced by High-Fat Diet through Enhanced Signaling of mTOR. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2017; 41:598-608. http://www.ncbi.nlm.nih.gov/pubmed/?term=28214901
  10. Liang J, Yin K, Cao X et al. Attenuation of Low Ambient Temperature-Induced Myocardial Hypertrophy by Atorvastatin via Promoting Bcl-2 Expression. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2017; 41:286-295. http://www.ncbi.nlm.nih.gov/pubmed/?term=28214881
  11. Morel J, Hargreaves I, Brealey D et al. Simvastatin pre-treatment improves survival and mitochondrial function in a three-day fluid-resuscitated rat model of sepsis. Clinical science (London, England : 1979) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28202686
  12. Li SJ, Wang XJ, Hu JB et al. Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy. Drug delivery 2017; 24:402-413. http://www.ncbi.nlm.nih.gov/pubmed/?term=28165814
  13. Liao WC, Huang MZ, Wang ML et al. Statin Decreases Helicobacter pylori Burden in Macrophages by Promoting Autophagy. Frontiers in cellular and infection microbiology 2016; 6:203. http://www.ncbi.nlm.nih.gov/pubmed/?term=28144585
  14. Ji T, Wentian L, Yukun Z et al. Simvastatin Inhibits IL-1beta-Induced Apoptosis and Extracellular Matrix Degradation by Suppressing the NF-kB and MAPK Pathways in Nucleus Pulposus Cells. Inflammation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28188410
  15. Pinho-Ribeiro V, Melo AC, Kennedy-Feitosa E et al. Atorvastatin and Simvastatin Promoted Mouse Lung Repair After Cigarette Smoke-Induced Emphysema. Inflammation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28251446
  16. Riekes MK, Dereymaker A, Berben P et al. Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters. Int J Pharm 2017; 520:49-58. http://www.ncbi.nlm.nih.gov/pubmed/?term=28153650
  17. Masaeli R, T SJK, Dinarvand R et al. Preparation, Characterization and Evaluation of Drug Release Properties of Simvastatin-loaded PLGA Microspheres. Iranian journal of pharmaceutical research : IJPR 2016; 15:205-211. http://www.ncbi.nlm.nih.gov/pubmed/?term=28228818
  18. Chhatriwalla AK, Rader DJ. Intracoronary Imaging, Reverse Cholesterol Transport, and Transcriptomics: Precision Medicine in CAD? J Am Coll Cardiol 2017; 69:641-643. http://www.ncbi.nlm.nih.gov/pubmed/?term=28183507
  19. Kanshana JS, Khanna V, Singh V et al. Progression and characterization of the accelerated atherosclerosis in iliac artery of New Zealand White rabbits: effect of Simvastatin. Journal of cardiovascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207427
  20. Wei L, Chen JS, Lin HT et al. Atorvastatin from target screening attenuates endothelial cell tube formation and migration by regulating urokinase receptor-related signaling pathway and F/G actin. Journal of the Chinese Medical Association : JCMA 2017; 80:86-95. http://www.ncbi.nlm.nih.gov/pubmed/?term=28159489
  21. Fraunberger P, Grone E, Grone HJ et al. Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. Journal of inflammation (London, England) 2017; 14:3. http://www.ncbi.nlm.nih.gov/pubmed/?term=28167864
  22. Chang Y, Li S, Guo W et al. Simvastatin protects human melanocytes from H2O2-induced oxidative stress by activating Nrf2. The Journal of investigative dermatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28174051
  23. Sohn HM, Hwang JY, Ryu JH et al. Simvastatin protects ischemic spinal cord injury from cell death and cytotoxicity through decreasing oxidative stress: in vitro primary cultured rat spinal cord model under oxygen and glucose deprivation-reoxygenation conditions. Journal of orthopaedic surgery and research 2017; 12:36. http://www.ncbi.nlm.nih.gov/pubmed/?term=28241838
  24. Messora MR, Apolinario Vieira GH, Vanderlei JM et al. Rosuvastatin promotes benefits on induced periodontitis in hypertensive rats. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28256038
  25. Luu W, Gelissen IC, Brown AJ. Manipulating Cholesterol Status Within Cells. Methods in molecular biology (Clifton, N.J.) 2017; 1583:41-52. http://www.ncbi.nlm.nih.gov/pubmed/?term=28205165
  26. Imanparast F, Faramarzi MA, Vatannejad A et al. mZD7349 peptide-conjugated PLGA nanoparticles directed against VCAM-1 for targeted delivery of simvastatin to restore dysfunctional HUVECs. Microvascular research 2017; 112:14-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=28161429
  27. Oliveira KA, Dal-Cim T, Lopes FG et al. Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28181188
  28. Kang SY, Lee SB, Kim HJ et al. Autophagic modulation by rosuvastatin prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson's disease. Neurosci Lett 2017; 642:20-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=28137648
  29. Mahmood A, Goussev A, Kazmi H et al. Simvastatin Provides Long-Lasting Benefits after Traumatic Brain Injury in Rats: 937. Neurosurgery 2009; 65:413. http://www.ncbi.nlm.nih.gov/pubmed/?term=28173370
  30. Yoo RJ, Kim MH, Woo SK et al. Monitoring of macrophage accumulation in statin-treated atherosclerotic mouse model using sodium iodide symporter imaging system. Nuclear medicine and biology 2017; 48:45-51. http://www.ncbi.nlm.nih.gov/pubmed/?term=28208058
  31. Elahi MM, Matata BM. Effects of maternal high-fat diet and statin treatment on bone marrow endothelial progenitor cells and cardiovascular risk factors in female mice offspring fed a similar diet. Nutrition 2017; 35:6-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=28241992
  32. Ma H, Liang WJ, Shan MR et al. Pravastatin activates activator protein 2 alpha to argument the angiotensin II-induced abdominal aortic aneurysms. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28179583
  33. Wang XL, Zhang T, Hu LH et al. Comparison of Effects of Different Statins on Contrast-Induced Acute Kidney Injury in Rats: Histopathological and Biochemical Findings. Oxidative medicine and cellular longevity 2017; 2017:6282486. http://www.ncbi.nlm.nih.gov/pubmed/?term=28243357
  34. Zang YY, Li YM, Yin Y et al. Discovery and quantitative structure-activity relationship study of lepidopteran HMG-CoA reductase inhibitors as selective insecticides. Pest management science 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28247468
  35. Balan A, Szaingurten-Solodkin I, Swissa SS et al. The effects of pravastatin on the normal human placenta: Lessons from ex-vivo models. PLoS One 2017; 12:e0172174. http://www.ncbi.nlm.nih.gov/pubmed/?term=28199380
  36. Liu PC, Lu G, Deng Y et al. Inhibition of NF-kappaB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy. PLoS One 2017; 12:e0171157. http://www.ncbi.nlm.nih.gov/pubmed/?term=28135339
  37. Park J, Kwon OS, Cho SY et al. Chronic administration of atorvastatin could partially ameliorate erectile function in streptozotocin-induced diabetic rats. PLoS One 2017; 12:e0172751. http://www.ncbi.nlm.nih.gov/pubmed/?term=28245261
  38. Southern WM, Nichenko AS, Shill DD et al. Skeletal muscle metabolic adaptations to endurance exercise training are attainable in mice with simvastatin treatment. PLoS One 2017; 12:e0172551. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207880
  39. Sigala F, Efentakis P, Karageorgiadi D et al. Reciprocal regulation of eNOS, H2S and CO-synthesizing enzymes in human atheroma: Correlation with plaque stability and effects of simvastatin. Redox biology 2017; 12:70-81. http://www.ncbi.nlm.nih.gov/pubmed/?term=28214453
  40. Liang Z, Li W, Liu J et al. Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells. Scientific reports 2017; 7:41776. http://www.ncbi.nlm.nih.gov/pubmed/?term=28150753
  41. Luo Y, Chen Y, Ma H et al. Enhancing the biocatalytic manufacture of the key intermediate of atorvastatin by focused directed evolution of halohydrin dehalogenase. Scientific reports 2017; 7:42064. http://www.ncbi.nlm.nih.gov/pubmed/?term=28165015
  42. Ahsan MN, Prasad Verma PR. Solidified self nano-emulsifying drug delivery system of rosuvastatin calcium to treat diet-induced hyperlipidemia in rat: in vitro and in vivo evaluations. Therapeutic delivery 2017; 8:125-136. http://www.ncbi.nlm.nih.gov/pubmed/?term=28145826
  43. El-Ashmawy NE, Khedr EG, El-Bahrawy HA, Al-Tantawy SM. Chemopreventive effect of omega-3 polyunsaturated fatty acids and atorvastatin in rats with bladder cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017; 39:1010428317692254. http://www.ncbi.nlm.nih.gov/pubmed/?term=28218036

Cancer

  1. Wu X, Song M, Qiu P et al. Synergistic chemopreventive effects of nobiletin and atorvastatin on colon carcinogenesis. Carcinogenesis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207072
  2. Wang ST, Ho HJ, Lin JT et al. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell death & disease 2017; 8:e2626. http://www.ncbi.nlm.nih.gov/pubmed/?term=28230855
  3. Liu X, Li J, Schild SE et al. Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. Journal of cancer therapy 2017; 8:73-85. http://www.ncbi.nlm.nih.gov/pubmed/?term=28239505
  4. Seckl MJ, Ottensmeier CH, Cullen M et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017:Jco2016697391. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240967
  5. Yokomichi H, Nagai A, Hirata M et al. Statin use and all-cause and cancer mortality: BioBank Japan cohort. Journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28196737
  6. Kapoor S. Rosuvastatin and Its Evolving Role as a Vascular Remodeling and Antiproliferative Agent in Different Systemic Malignancies. J Pharmacol Exp Ther 2017; 360:434. http://www.ncbi.nlm.nih.gov/pubmed/?term=28188271
  7. Hung MS, Chen IC, Lee CP et al. Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One 2017; 12:e0171137. http://www.ncbi.nlm.nih.gov/pubmed/?term=28158206
  8. Liu PC, Lu G, Deng Y et al. Inhibition of NF-kappaB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy. PLoS One 2017; 12:e0171157. http://www.ncbi.nlm.nih.gov/pubmed/?term=28135339
  9. El-Ashmawy NE, Khedr EG, El-Bahrawy HA, Al-Tantawy SM. Chemopreventive effect of omega-3 polyunsaturated fatty acids and atorvastatin in rats with bladder cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017; 39:1010428317692254. http://www.ncbi.nlm.nih.gov/pubmed/?term=28218036
  10. Richard PO, Ahmad AE, Bashir S et al. Effect of statins as a secondary chemopreventive agent among individuals with non-muscle-invasive bladder cancer: A population-based analysis. Urologic oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28190747

Children

  1. Kishi T, Rider LG, Pak K et al. Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1*07:01 and Severe Myositis in Pediatric Myositis Patients. Arthritis care & research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28129483
  2. Kaminska E, Hennig M, Brandt A et al. [Treatment with statins in children with familial hypercholesterolemia]. Developmental period medicine 2016; 20:328-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=28216488
  3. Hung MS, Chen IC, Lee CP et al. Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One 2017; 12:e0171137. http://www.ncbi.nlm.nih.gov/pubmed/?term=28158206

Cost-effectiveness

  1. Mayor S. Single liver enzyme test in statin patients cuts full testing by a quarter, study finds. Bmj 2017; 356:j515. http://www.ncbi.nlm.nih.gov/pubmed/?term=28143852
  2. Krumme AA, Sanfelix-Gimeno G, Franklin JM et al. Can purchasing information be used to predict adherence to cardiovascular medications? An analysis of linked retail pharmacy and insurance claims data. BMJ Open 2016; 6:e011015. http://www.ncbi.nlm.nih.gov/pubmed/?term=28186924
  3. Stam-Slob MC, van der Graaf Y, Greving JP et al. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28214794
  4. Jeong YJ, Kim H, Baik SJ et al. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea. Journal of clinical pharmacy and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28251662

CVD

  1. Einarsen E, Cramariuc D, Lonnebakken MT et al. Comparison of Frequency of Ischemic Cardiovascular Events in Patients With Aortic Stenosis With Versus Without Asymmetric Septal Hypertrophy (from the SEAS Trial). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28132685
  2. Chang TI, Streja E, Soohoo M et al. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28193609
  3. Lin Wu FL, Wang J, Ho W et al. Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28190615
  4. Lee CJ, Oh J, Lee SH et al. Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study. J Hypertens 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28129248
  5. Reichert K, Pereira do Carmo HR, Galluce Torina A et al. Correction: Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism. PLoS One 2017; 12:e0172453. http://www.ncbi.nlm.nih.gov/pubmed/?term=28196119
  6. Sepehri Z, Masoumi M, Ebrahimi N et al. Correction: Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-beta, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension. PLoS One 2017; 12:e0172404. http://www.ncbi.nlm.nih.gov/pubmed/?term=28192516
  7. Ye Z, Lu H, Su Q et al. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis. PLoS One 2017; 12:e0171682. http://www.ncbi.nlm.nih.gov/pubmed/?term=28231287

Endothelium/Inflammation

  1. Toribio M, Fitch KV, Sanchez L et al. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in intrepid: a randomized trial in HIV. Aids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28252528

Familial Hypercholesterolemia

  1. Bruckert E, Kalmykova O, Bittar R et al. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Atherosclerosis 2017; 257:130-137. http://www.ncbi.nlm.nih.gov/pubmed/?term=28131047
  2. Kwok S, Pang J, Adam S et al. An online questionnaire survey of UK general practitioners' knowledge and management of familial hypercholesterolaemia. BMJ Open 2016; 6:e012691. http://www.ncbi.nlm.nih.gov/pubmed/?term=28186938
  3. Kaminska E, Hennig M, Brandt A et al. [Treatment with statins in children with familial hypercholesterolemia]. Developmental period medicine 2016; 20:328-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=28216488
  4. Mabuchi H. Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28179607
  5. Vrablik M, Freiberger T, Blaha V, Ceska R. [Severe familial hypercholesterolemia treatment]. Vnitr Lek 2016; 62:895-901. http://www.ncbi.nlm.nih.gov/pubmed/?term=28128576

Generics

  1. Hansen RA, Qian J, Berg R et al. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28152215

Genetics

  1. Natarajan P, Young R, Stitziel NO et al. Polygenic Risk Score Identifies Subgroup with Higher Burden of Atherosclerosis and Greater Relative Benefit from Statin Therapy in the Primary Prevention Setting. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28223407
  2. Rumyantsev NA, Kukes VG, Kazakov RE et al. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy]. Ter Arkh 2017; 89:82-88. http://www.ncbi.nlm.nih.gov/pubmed/?term=28252633

Guidelines

  1. Kuehn BM. Preventive Statin Use Recommended by US Task Force. Circulation 2017; 135:806-807. http://www.ncbi.nlm.nih.gov/pubmed/?term=28223326
  2. Kaminska E, Hennig M, Brandt A et al. [Treatment with statins in children with familial hypercholesterolemia]. Developmental period medicine 2016; 20:328-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=28216488
  3. Pletcher MJ, Pignone M, Jarmul JA et al. Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28188251
  4. Li YH, Ueng KC, Jeng JS et al. 2017 Taiwan lipid guidelines for high risk patients. Journal of the Formosan Medical Association = Taiwan yi zhi 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28242176
  5. Blumenthal RS, Gluckman TJ, Martin SS. Trends in the Use of Moderate-Intensity to High-Intensity Statin and Nonstatin Lipid-Lowering Therapy: Turning Off the Faucet Is Much More Valuable Than Mopping Up the Floor. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28249079
  6. Pokharel Y, Tang F, Jones PG et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28249067 

LDL- related parameters

  1. Kim HS, Lee H, Lee SH et al. Use of Moderate-Intensity Statins for Low-Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28165667
  2. Steen DL, Khan I, Ansell D et al. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open 2017; 7:e013255. http://www.ncbi.nlm.nih.gov/pubmed/?term=28213597
  3. Whayne TF. Low-Density Lipoprotein Cholesterol (LDL-C): How Low? Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28245773
  4. Tecson KM, Panettiere-Kennedy KS, Won JI et al. Relation between proprotein convertase subtilisin/kexin type 9 and directly measured low-density lipoprotein cholesterol. Proceedings (Baylor University. Medical Center) 2017; 30:16-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=28127122
  5. Zhang Y, Wei DD, Yuan RR et al. [Effects of ApoE gene polymorphism on the efficacy of atorvastatin in the treatment of hyperlipidemia]. Zhonghua yi xue za zhi 2017; 97:291-294. http://www.ncbi.nlm.nih.gov/pubmed/?term=28162160 

Meta-analyses

  1. Sahebkar A, Simental-Mendia LE, Watts GF et al. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med 2017; 15:22. http://www.ncbi.nlm.nih.gov/pubmed/?term=28153024
  2. E D, E S, G D et al. Effect of ezetimibe on plasma adipokines: A Systematic review and meta-analysis. Br J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28166606
  3. Zheng YX, Zhou PC, Zhou RR, Fan XG. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. European journal of gastroenterology & hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240613
  4. Xiong B, Nie D, Cao Y et al. Preoperative Statin Treatment for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomised Controlled Trials. Heart, lung & circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28242291
  5. Brinjikji W, Lehman VT, Kallmes DF et al. The effects of statin therapy on carotid plaque composition and volume: A systematic review and meta-analysis. Journal of neuroradiology. Journal de neuroradiologie 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28187866
  6. Mozetic V, Freitas CG, Riera R. Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review. JMIR research protocols 2017; 6:e30. http://www.ncbi.nlm.nih.gov/pubmed/?term=28228373
  7. Lopes Nunes JP. Statins in primary prevention, impact on mortality. A meta-analysis study. Minerva cardioangiologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28249380
  8. Navarese EP, Gurbel PA, Andreotti F et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One 2017; 12:e0168726. http://www.ncbi.nlm.nih.gov/pubmed/?term=28151965
  9. Ye Z, Lu H, Su Q et al. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis. PLoS One 2017; 12:e0171682. http://www.ncbi.nlm.nih.gov/pubmed/?term=28231287
  10. Akhigbe T, Zolnourian A, Bulters D. Cholesterol-reducing agents for treatment of aneurysmal subarachnoid haemorrhage: systematic review and meta-analyses of randomized controlled trials. World neurosurgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28192263

Metabolic Syndrome - Diabetes

  1. Mozetic V, Freitas CG, Riera R. Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review. JMIR research protocols 2017; 6:e30. http://www.ncbi.nlm.nih.gov/pubmed/?term=28228373
  2. Standl E, Schnell O, McGuire DK et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. The lancet. Diabetes & endocrinology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28131656
  3. Taylor BA, Ng J, Stone A et al. Effects of statin therapy on weight loss and diabetes in bariatric patients. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28159561

New Treatments

  1. Giugliano RP, Mach F, Zavitz K et al. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207168
  2. Gadkar K, Budha N, Baruch A et al. A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations. CPT Pharmacometrics Syst Pharmacol 2014; 3:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28188981
  3. Schmitz J, Gouni-Berthold I. Anti-PCSK9 antibodies: A new era in the treatment of dyslipidemia. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28137217
  4. Leiter LA, Zamorano JL, Bujas-Bobanovic M et al. Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28206704
  5. Standl E, Schnell O, McGuire DK et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. The lancet. Diabetes & endocrinology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28131656
  6. Chen J. [Non-statin therapies for dylipidemia]. Zhonghua nei ke za zhi 2017; 56:176-178. http://www.ncbi.nlm.nih.gov/pubmed/?term=28253596

Pleiotropic effects of statins

  1. Komatsu R, Yilmaz HO, You J et al. Lack of Association between Preoperative Statin Use and Respiratory and Neurologic Complications after Cardiac Surgery. Anesthesiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207437
  2. Panes O, Gonzalez C, Hidalgo P et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2016; 257:164-171. http://www.ncbi.nlm.nih.gov/pubmed/?term=28142075
  3. Han W, Li J, Tang H, Sun L. Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level. Biochem Biophys Res Commun 2017; 484:396-402. http://www.ncbi.nlm.nih.gov/pubmed/?term=28131832
  4. Hirooka S, Ueno M, Fukuda S et al. Effects of Simvastatin on Alveolar Regeneration and Its Relationship to Exposure in Mice with Dexamethasone-Induced Emphysema. Biological & pharmaceutical bulletin 2017; 40:155-160. http://www.ncbi.nlm.nih.gov/pubmed/?term=28154254
  5. Raymakers AJ, Sadatsafavi M, Sin DD et al. The impact of statin use on all-cause mortality in patients with COPD: a population based cohort study. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28202342
  6. Zheng YX, Zhou PC, Zhou RR, Fan XG. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. European journal of gastroenterology & hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240613
  7. Kishta SS, Kishta SA, El-Shenawy R. Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. F1000Research 2016; 5:223. http://www.ncbi.nlm.nih.gov/pubmed/?term=27583130
  8. Liao WC, Huang MZ, Wang ML et al. Statin Decreases Helicobacter pylori Burden in Macrophages by Promoting Autophagy. Frontiers in cellular and infection microbiology 2016; 6:203. http://www.ncbi.nlm.nih.gov/pubmed/?term=28144585
  9. Sirenko Y, Radchenko G. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2017; 24:85-93. http://www.ncbi.nlm.nih.gov/pubmed/?term=28150140
  10. Pinho-Ribeiro V, Melo AC, Kennedy-Feitosa E et al. Atorvastatin and Simvastatin Promoted Mouse Lung Repair After Cigarette Smoke-Induced Emphysema. Inflammation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28251446
  11. N P, Abhilash A, Saquib S et al. Clinical Efficacy of Subgingivally Delivered 1.2 mg Simvastatin in the Treatment of Patients with Aggressive Periodontitis: A Randomized Controlled Clinical Trial. The International journal of periodontics & restorative dentistry 2017; 37:e135-e141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28196160
  12. Rothenberg FG, Clay MB, Jamali H, Vandivier-Pletsch RH. Systematic review of beta blocker, aspirin, and statin in critically ill patients: importance of severity of illness and cardiac troponin. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28138011
  13. Sohn HM, Hwang JY, Ryu JH et al. Simvastatin protects ischemic spinal cord injury from cell death and cytotoxicity through decreasing oxidative stress: in vitro primary cultured rat spinal cord model under oxygen and glucose deprivation-reoxygenation conditions. Journal of orthopaedic surgery and research 2017; 12:36. http://www.ncbi.nlm.nih.gov/pubmed/?term=28241838
  14. Messora MR, Apolinario Vieira GH, Vanderlei JM et al. Rosuvastatin promotes benefits on induced periodontitis in hypertensive rats. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28256038
  15. Mozetic V, Freitas CG, Riera R. Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review. JMIR research protocols 2017; 6:e30. http://www.ncbi.nlm.nih.gov/pubmed/?term=28228373
  16. Kang SY, Lee SB, Kim HJ et al. Autophagic modulation by rosuvastatin prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson's disease. Neurosci Lett 2017; 642:20-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=28137648
  17. Mahmood A, Goussev A, Kazmi H et al. Simvastatin Provides Long-Lasting Benefits after Traumatic Brain Injury in Rats: 937. Neurosurgery 2009; 65:413. http://www.ncbi.nlm.nih.gov/pubmed/?term=28173370
  18. Ma H, Liang WJ, Shan MR et al. Pravastatin activates activator protein 2 alpha to argument the angiotensin II-induced abdominal aortic aneurysms. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28179583
  19. Drechsler H, Ayers C, Cutrell J et al. Current use of statins reduces risk of HIV rebound on suppressive HAART. PLoS One 2017; 12:e0172175. http://www.ncbi.nlm.nih.gov/pubmed/?term=28249009
  20. Liang Z, Li W, Liu J et al. Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells. Scientific reports 2017; 7:41776. http://www.ncbi.nlm.nih.gov/pubmed/?term=28150753

Primary Prevention

  1. Natarajan P, Young R, Stitziel NO et al. Polygenic Risk Score Identifies Subgroup with Higher Burden of Atherosclerosis and Greater Relative Benefit from Statin Therapy in the Primary Prevention Setting. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28223407
  2. McKibben RA, Al Rifai M, Mathews LM, Michos ED. Primary Prevention of Atherosclerotic Cardiovascular Disease in Women. Current cardiovascular risk reports 2016; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28149430
  3. Lee CJ, Oh J, Lee SH et al. Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study. J Hypertens 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28129248
  4. Lopes Nunes JP. Statins in primary prevention, impact on mortality. A meta-analysis study. Minerva cardioangiologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28249380

Registry data

  1. Brinjikji W, Cloft H, Cekirge S et al. Lack of Association between Statin Use and Angiographic and Clinical Outcomes after Pipeline Embolization for Intracranial Aneurysms. AJNR. American journal of neuroradiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28154128
  2. Komatsu R, Yilmaz HO, You J et al. Lack of Association between Preoperative Statin Use and Respiratory and Neurologic Complications after Cardiac Surgery. Anesthesiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207437
  3. Kim HS, Lee H, Lee SH et al. Use of Moderate-Intensity Statins for Low-Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28165667
  4. Krumme AA, Sanfelix-Gimeno G, Franklin JM et al. Can purchasing information be used to predict adherence to cardiovascular medications? An analysis of linked retail pharmacy and insurance claims data. BMJ Open 2016; 6:e011015. http://www.ncbi.nlm.nih.gov/pubmed/?term=28186924
  5. Homer K, Robson J, Solaiman S et al. Reducing liver function tests for statin monitoring: an observational comparison of two clinical commissioning groups. Br J Gen Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28137784
  6. Ballotta E, Toniato A, Farina F, Baracchini C. Effects of preoperative statin use on perioperative outcomes of carotid endarterectomy. Brain and behavior 2017; 7:e00597. http://www.ncbi.nlm.nih.gov/pubmed/?term=28127515
  7. Raymakers AJ, Sadatsafavi M, Sin DD et al. The impact of statin use on all-cause mortality in patients with COPD: a population based cohort study. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28202342
  8. Antoniou T, Macdonald EM, Yao Z et al. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2017; 189:E4-e10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28246253
  9. Antoniou T, Mamdani M, Juurlink D. Response to "Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation". CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2017; 189:E326. http://www.ncbi.nlm.nih.gov/pubmed/?term=28246232
  10. Kadohira T, Mintz GS, Souza CF et al. Impact of chronic statin therapy on clinical presentation and underlying lesion morphology in patients undergoing percutaneous intervention: an ADAPT-DES IVUS substudy. Coronary artery disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240675
  11. Jones M, Tett S, Peeters GM et al. New-Onset Diabetes After Statin Exposure in Elderly Women: The Australian Longitudinal Study on Women's Health. Drugs Aging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28138911
  12. Munkhaugen J, Sverre E, Otterstad JE et al. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol 2017:2047487317693134. http://www.ncbi.nlm.nih.gov/pubmed/?term=28196429
  13. Wallert J, Lissaker C, Madison G et al. Young adulthood cognitive ability predicts statin adherence in middle-aged men after first myocardial infarction: A Swedish National Registry study. Eur J Prev Cardiol 2017:2047487317693951. http://www.ncbi.nlm.nih.gov/pubmed/?term=28195516
  14. Protty MB, Lacey A, Hayes J, Freeman P. Statins for secondary prevention: clinical use in patients with acute coronary syndrome in Wales. Future cardiology 2017; 13:137-141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28185473
  15. Lin Wu FL, Wang J, Ho W et al. Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28190615
  16. Pletcher MJ, Pignone M, Jarmul JA et al. Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28188251
  17. Liu X, Li J, Schild SE et al. Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. Journal of cancer therapy 2017; 8:73-85. http://www.ncbi.nlm.nih.gov/pubmed/?term=28239505
  18. Yokomichi H, Nagai A, Hirata M et al. Statin use and all-cause and cancer mortality: BioBank Japan cohort. Journal of epidemiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28196737
  19. Lee CJ, Oh J, Lee SH et al. Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study. J Hypertens 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28129248
  20. Guertin JR, Rahme E, LeLorier J. Use of Continuous Exposure Variables when Examining Dose-Dependent Pharmacological Effects - Application to the Association between Exposure to Higher Statin Doses and the Incidence of Diabetes. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 2017; 24:5-15. http://www.ncbi.nlm.nih.gov/pubmed/?term=28186711
  21. Mansi IA, English JL, Morris MJ et al. Statins for primary prevention in physically active individuals: Do the risks outweigh the benefits? Journal of science and medicine in sport 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28185810
  22. Blumenthal RS, Gluckman TJ, Martin SS. Trends in the Use of Moderate-Intensity to High-Intensity Statin and Nonstatin Lipid-Lowering Therapy: Turning Off the Faucet Is Much More Valuable Than Mopping Up the Floor. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28249079
  23. Pokharel Y, Tang F, Jones PG et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28249067
  24. Wu YL, Saver JL, Chen PC et al. Effect of statin use on clinical outcomes in ischemic stroke patients with atrial fibrillation. Medicine (Baltimore) 2017; 96:e5918. http://www.ncbi.nlm.nih.gov/pubmed/?term=28151869
  25. McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28176447
  26. Drechsler H, Ayers C, Cutrell J et al. Current use of statins reduces risk of HIV rebound on suppressive HAART. PLoS One 2017; 12:e0172175. http://www.ncbi.nlm.nih.gov/pubmed/?term=28249009
  27. Hung MS, Chen IC, Lee CP et al. Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One 2017; 12:e0171137. http://www.ncbi.nlm.nih.gov/pubmed/?term=28158206
  28. Richard PO, Ahmad AE, Bashir S et al. Effect of statins as a secondary chemopreventive agent among individuals with non-muscle-invasive bladder cancer: A population-based analysis. Urologic oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28190747

Renal Disease

  1. Chang TI, Streja E, Soohoo M et al. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28193609
  2. Hohenstein B. Lipoprotein(a) in nephrological patients. Clinical research in cardiology supplements 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28181057
  3. Xiong B, Nie D, Cao Y et al. Preoperative Statin Treatment for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomised Controlled Trials. Heart, lung & circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28242291
  4. Mikolasevic I, Zutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. International journal of nephrology and renovascular disease 2017; 10:35-45. http://www.ncbi.nlm.nih.gov/pubmed/?term=28223836
  5. Wang XL, Zhang T, Hu LH et al. Comparison of Effects of Different Statins on Contrast-Induced Acute Kidney Injury in Rats: Histopathological and Biochemical Findings. Oxidative medicine and cellular longevity 2017; 2017:6282486. http://www.ncbi.nlm.nih.gov/pubmed/?term=28243357
  6. Sana T, Aslam B, Aslam N et al. Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. Pak J Pharm Sci 2016; 29:2321-2326. http://www.ncbi.nlm.nih.gov/pubmed/?term=28167473
  7. Navarese EP, Gurbel PA, Andreotti F et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One 2017; 12:e0168726. http://www.ncbi.nlm.nih.gov/pubmed/?term=28151965
  8. Rumyantsev NA, Kukes VG, Kazakov RE et al. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy]. Ter Arkh 2017; 89:82-88. http://www.ncbi.nlm.nih.gov/pubmed/?term=28252633

Reviews

  1. Geifman N, Brinton RD, Kennedy RE et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimer's research & therapy 2017; 9:10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28212683
  2. Hoy SM. Pitavastatin: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28130659
  3. Falk E. Appropriate use of cholesterol-lowering therapy. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28236436
  4. Homer K, Robson J, Solaiman S et al. Reducing liver function tests for statin monitoring: an observational comparison of two clinical commissioning groups. Br J Gen Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28137784
  5. Durrington PN, Soran H. Cholesterol Levels Should Play a More Important Role in Identifying Statin Recipients. Circulation 2017; 135:627-629. http://www.ncbi.nlm.nih.gov/pubmed/?term=28193795
  6. Stone NJ, Robinson JG. Potential for Net Benefit Should Guide Preventive Therapy. Circulation 2017; 135:630-632. http://www.ncbi.nlm.nih.gov/pubmed/?term=28193796
  7. Hohenstein B. Lipoprotein(a) in nephrological patients. Clinical research in cardiology supplements 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28181057
  8. Haertter S, Huang F, Franca LR. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2017; 189:E325. http://www.ncbi.nlm.nih.gov/pubmed/?term=28246231
  9. McKibben RA, Al Rifai M, Mathews LM, Michos ED. Primary Prevention of Atherosclerotic Cardiovascular Disease in Women. Current cardiovascular risk reports 2016; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28149430
  10. Laakso M, Kuusisto J. Diabetes Secondary to Treatment with Statins. Current diabetes reports 2017; 17:10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28155189
  11. Schmitz J, Gouni-Berthold I. Anti-PCSK9 antibodies: A new era in the treatment of dyslipidemia. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28137217
  12. Whayne TF. Low-Density Lipoprotein Cholesterol (LDL-C): How Low? Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28245773
  13. Mikolasevic I, Zutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. International journal of nephrology and renovascular disease 2017; 10:35-45. http://www.ncbi.nlm.nih.gov/pubmed/?term=28223836
  14. Koh KK. What Is the Best Disease-Guided Approach to Statin? J Am Coll Cardiol 2017; 69:600. http://www.ncbi.nlm.nih.gov/pubmed/?term=28153119
  15. Kataoka Y, Andrews J, Puri R et al. Lipid Lowering Therapy to Modify Plaque Microstructures. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28239070
  16. Rothenberg FG, Clay MB, Jamali H, Vandivier-Pletsch RH. Systematic review of beta blocker, aspirin, and statin in critically ill patients: importance of severity of illness and cardiac troponin. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28138011
  17. Kapoor S. Rosuvastatin and Its Evolving Role as a Vascular Remodeling and Antiproliferative Agent in Different Systemic Malignancies. J Pharmacol Exp Ther 2017; 360:434. http://www.ncbi.nlm.nih.gov/pubmed/?term=28188271
  18. du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacology & therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28223230
  19. Broniarek I, Jarmuszkiewicz W. [Statins and mitochondria]. Postepy biochemii 2016; 62:77-84. http://www.ncbi.nlm.nih.gov/pubmed/?term=28132458
  20. Oscanoa Espinoza TJ, Paredes-Perez N, Lizaraso-Soto F. [Safety of statins]. Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) 2016; 73:263-278. http://www.ncbi.nlm.nih.gov/pubmed/?term=28152368
  21. Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Therapeutic advances in chronic disease 2017; 8:4-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28203346
  22. Tarantino N, Santoro F, De Gennaro L et al. Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag 2017; 13:29-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=28243111
  23. Vrablik M, Freiberger T, Blaha V, Ceska R. [Severe familial hypercholesterolemia treatment]. Vnitr Lek 2016; 62:895-901. http://www.ncbi.nlm.nih.gov/pubmed/?term=28128576
  24. Chen J. [Non-statin therapies for dylipidemia]. Zhonghua nei ke za zhi 2017; 56:176-178. http://www.ncbi.nlm.nih.gov/pubmed/?term=28253596

Safety and side effects

  1. Kishi T, Rider LG, Pak K et al. Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1*07:01 and Severe Myositis in Pediatric Myositis Patients. Arthritis care & research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28129483
  2. Ouweneel AB, van der Sluis RJ, Nahon JE et al. Simvastatin treatment aggravates the glucocorticoid insufficiency associated with hypocholesterolemia in mice. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28242047
  3. Mayor S. Single liver enzyme test in statin patients cuts full testing by a quarter, study finds. Bmj 2017; 356:j515. http://www.ncbi.nlm.nih.gov/pubmed/?term=28143852
  4. Mayor S. Statin side effects are strongest predictor of inadequate cholesterol control, study shows. Bmj 2017; 356:j869. http://www.ncbi.nlm.nih.gov/pubmed/?term=28219883
  5. Mikashinovich ZI, Belousova ES, Sarkisyan OG. Impairment of Energy-Dependent Processes in the Muscle Tissue as a Pathogenetic Mechanism of Statin-Induced Myopathy. Bulletin of experimental biology and medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28239789
  6. Mirza ZB, Hu S, Amorosa LF. Bone scintigraphy of severe hypercalcemia following simvastatin induced rhabdomyolysis. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases 2016; 13:257-261. http://www.ncbi.nlm.nih.gov/pubmed/?term=28228795
  7. Christopher-Stine L, Basharat P. Statin-associated immune-mediated myopathy: biology and clinical implications. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207435
  8. Koslik HJ, Meskimen AH, Golomb BA. Physicians' Experiences as Patients with Statin Side Effects: A Case Series. Drug safety - case reports 2017; 4:3. http://www.ncbi.nlm.nih.gov/pubmed/?term=28217821
  9. Jones M, Tett S, Peeters GM et al. New-Onset Diabetes After Statin Exposure in Elderly Women: The Australian Longitudinal Study on Women's Health. Drugs Aging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28138911
  10. Asping M, Stride N, Sogaard D et al. The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28246888
  11. Sreter KB, Barisic B, Popovic-Grle S. Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28257284
  12. Keating P, Young J, George P et al. Anti-HMGCR autoantibodies in self-limiting statin-induced myopathy. International journal of rheumatic diseases 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28185416
  13. Guertin JR, Rahme E, LeLorier J. Use of Continuous Exposure Variables when Examining Dose-Dependent Pharmacological Effects - Application to the Association between Exposure to Higher Statin Doses and the Incidence of Diabetes. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 2017; 24:5-15. http://www.ncbi.nlm.nih.gov/pubmed/?term=28186711
  14. Mansi IA, English JL, Morris MJ et al. Statins for primary prevention in physically active individuals: Do the risks outweigh the benefits? Journal of science and medicine in sport 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28185810
  15. Lai SW, Liao KF, Lin CL et al. Statins use and female lung cancer risk in Taiwan. The Libyan journal of medicine 2012; 7:20123. http://www.ncbi.nlm.nih.gov/pubmed/?term=28136089
  16. Oliveira KA, Dal-Cim T, Lopes FG et al. Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28181188
  17. Prajapati SK, Garabadu D, Krishnamurthy S. Coenzyme Q10 Prevents Mitochondrial Dysfunction and Facilitates Pharmacological Activity of Atorvastatin in 6-OHDA Induced Dopaminergic Toxicity in Rats. Neurotox Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28130746
  18. du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacology & therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28223230
  19. Southern WM, Nichenko AS, Shill DD et al. Skeletal muscle metabolic adaptations to endurance exercise training are attainable in mice with simvastatin treatment. PLoS One 2017; 12:e0172551. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207880
  20. Broniarek I, Jarmuszkiewicz W. [Statins and mitochondria]. Postepy biochemii 2016; 62:77-84. http://www.ncbi.nlm.nih.gov/pubmed/?term=28132458
  21. Oscanoa Espinoza TJ, Paredes-Perez N, Lizaraso-Soto F. [Safety of statins]. Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) 2016; 73:263-278. http://www.ncbi.nlm.nih.gov/pubmed/?term=28152368
  22. Oztas M, Ugurlu S, Aydin O. Atorvastatin-induced dermatomyositis. Rheumatology international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28238074
  23. Bakker EA, Timmers S, Hopman MT et al. Association Between Statin Use and Prevalence of Exercise-Related Injuries: A Cross-Sectional Survey of Amateur Runners in the Netherlands. Sports medicine (Auckland, N.Z.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28138920
  24. Rumyantsev NA, Kukes VG, Kazakov RE et al. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy]. Ter Arkh 2017; 89:82-88. http://www.ncbi.nlm.nih.gov/pubmed/?term=28252633

Stroke and CNS

  1. Brinjikji W, Cloft H, Cekirge S et al. Lack of Association between Statin Use and Angiographic and Clinical Outcomes after Pipeline Embolization for Intracranial Aneurysms. AJNR. American journal of neuroradiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28154128
  2. Geifman N, Brinton RD, Kennedy RE et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimer's research & therapy 2017; 9:10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28212683
  3. Nakamura M, Fukukawa T, Kitagawa K et al. ANNALS EXPRESS: Ten-year standardization of lipids and high-sensitivity C-reactive protein in a randomized controlled trial to assess effects of statins on secondary stroke prevention: Japan Statin Treatment Against Recurrent Stroke (J-STARS). Annals of clinical biochemistry 2017:4563217693651. http://www.ncbi.nlm.nih.gov/pubmed/?term=28135841
  4. Ballotta E, Toniato A, Farina F, Baracchini C. Effects of preoperative statin use on perioperative outcomes of carotid endarterectomy. Brain and behavior 2017; 7:e00597. http://www.ncbi.nlm.nih.gov/pubmed/?term=28127515
  5. Antoniou T, Macdonald EM, Yao Z et al. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2017; 189:E4-e10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28246253
  6. Antoniou T, Mamdani M, Juurlink D. Response to "Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation". CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2017; 189:E326. http://www.ncbi.nlm.nih.gov/pubmed/?term=28246232
  7. Haertter S, Huang F, Franca LR. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2017; 189:E325. http://www.ncbi.nlm.nih.gov/pubmed/?term=28246231
  8. Wu YL, Saver JL, Chen PC et al. Effect of statin use on clinical outcomes in ischemic stroke patients with atrial fibrillation. Medicine (Baltimore) 2017; 96:e5918. http://www.ncbi.nlm.nih.gov/pubmed/?term=28151869
  9. Kramer AH, Bleck TP, Nathan BA et al. Statin Use Was not Associated with Less Vasospasm or Improved Outcome after Subarachnoid Hemorrhage. Neurosurgery 2008; 63:E1209. http://www.ncbi.nlm.nih.gov/pubmed/?term=28184873
  10. Lynch JR, McGirt M, Laskowitz DT et al. 871 Simvastatin Reduces Vasospasm after Aneurysmal Subarachnoid Hemorrhage: Results of a Pilot Randomized Clinical Trial. Neurosurgery 2005; 57:420. http://www.ncbi.nlm.nih.gov/pubmed/?term=28184829
  11. Parra A, Kreiter KT, Williams S et al. Effect of Prior Statin Use on Functional Outcome and Delayed Vasospasm after Acute Aneurysmal Subarachnoid Hemorrhage: A Matched Controlled Cohort Study. Neurosurgery 2005; 56:476-484. http://www.ncbi.nlm.nih.gov/pubmed/?term=28184638
  12. Tseng MY, Czosnyka M, Pickard JD, Kirkpatrick PJ. Effects of Acute Treatment with Pravastatin on Cerebral Autoregulation in Patients after Aneurysmal Subarachnoid Hemorrhage 810. Neurosurgery 2006; 59:456. http://www.ncbi.nlm.nih.gov/pubmed/?term=28180674
  13. Akhigbe T, Zolnourian A, Bulters D. Cholesterol-reducing agents for treatment of aneurysmal subarachnoid haemorrhage: systematic review and meta-analyses of randomized controlled trials. World neurosurgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28192263 

Triglycerides HDL-C and Non HDL-C

  1. Chang TI, Streja E, Soohoo M et al. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28193609  

Trials

  1. Toribio M, Fitch KV, Sanchez L et al. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in intrepid: a randomized trial in HIV. Aids 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28252528
  2. Einarsen E, Cramariuc D, Lonnebakken MT et al. Comparison of Frequency of Ischemic Cardiovascular Events in Patients With Aortic Stenosis With Versus Without Asymmetric Septal Hypertrophy (from the SEAS Trial). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28132685
  3. Nakamura M, Fukukawa T, Kitagawa K et al. ANNALS EXPRESS: Ten-year standardization of lipids and high-sensitivity C-reactive protein in a randomized controlled trial to assess effects of statins on secondary stroke prevention: Japan Statin Treatment Against Recurrent Stroke (J-STARS). Annals of clinical biochemistry 2017:4563217693651. http://www.ncbi.nlm.nih.gov/pubmed/?term=28135841
  4. Panes O, Gonzalez C, Hidalgo P et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2016; 257:164-171. http://www.ncbi.nlm.nih.gov/pubmed/?term=28142075
  5. Giugliano RP, Mach F, Zavitz K et al. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28207168
  6. Chang TI, Streja E, Soohoo M et al. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28193609
  7. Leiter LA, Zamorano JL, Bujas-Bobanovic M et al. Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28206704
  8. Nord JW, Jr., Berry A, Stults B et al. Evaluation of the Effectiveness of a Patient-Centered Educational Mailer Designed to Improve Statin Adherence: A Pragmatic Trial. EGEMS (Washington, DC) 2016; 4:1256. http://www.ncbi.nlm.nih.gov/pubmed/?term=28203610
  9. Asping M, Stride N, Sogaard D et al. The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28246888
  10. Sirenko Y, Radchenko G. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2017; 24:85-93. http://www.ncbi.nlm.nih.gov/pubmed/?term=28150140
  11. N P, Abhilash A, Saquib S et al. Clinical Efficacy of Subgingivally Delivered 1.2 mg Simvastatin in the Treatment of Patients with Aggressive Periodontitis: A Randomized Controlled Clinical Trial. The International journal of periodontics & restorative dentistry 2017; 37:e135-e141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28196160
  12. Bischoff-Ferrari HA, Fischer K, Orav EJ et al. Statin Use and 25-Hydroxyvitamin D Blood Level Response to Vitamin D Treatment of Older Adults. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240766
  13. Seckl MJ, Ottensmeier CH, Cullen M et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017:Jco2016697391. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240967
  14. Morelli VM, Lijfering WM, Rosendaal FR, Cannegieter SC. Lipid levels and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Journal of thrombosis and haemostasis : JTH 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28135040
  15. Lee CJ, Choi S, Cheon DH et al. Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. Lipids Health Dis 2017; 16:49. http://www.ncbi.nlm.nih.gov/pubmed/?term=28245873
  16. Kramer AH, Bleck TP, Nathan BA et al. Statin Use Was not Associated with Less Vasospasm or Improved Outcome after Subarachnoid Hemorrhage. Neurosurgery 2008; 63:E1209. http://www.ncbi.nlm.nih.gov/pubmed/?term=28184873
  17. Lynch JR, McGirt M, Laskowitz DT et al. 871 Simvastatin Reduces Vasospasm after Aneurysmal Subarachnoid Hemorrhage: Results of a Pilot Randomized Clinical Trial. Neurosurgery 2005; 57:420. http://www.ncbi.nlm.nih.gov/pubmed/?term=28184829
  18. Parra A, Kreiter KT, Williams S et al. Effect of Prior Statin Use on Functional Outcome and Delayed Vasospasm after Acute Aneurysmal Subarachnoid Hemorrhage: A Matched Controlled Cohort Study. Neurosurgery 2005; 56:476-484. http://www.ncbi.nlm.nih.gov/pubmed/?term=28184638
  19. Liu Z, Hao H, Yin C et al. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28177908
  20. Taylor BA, Ng J, Stone A et al. Effects of statin therapy on weight loss and diabetes in bariatric patients. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28159561
  21. Soska V. [Notes on the HOPE-3 study]. Vnitr Lek 2016; 62:929-932. http://www.ncbi.nlm.nih.gov/pubmed/?term=28128582
  22. Zhang Y, Wei DD, Yuan RR et al. [Effects of ApoE gene polymorphism on the efficacy of atorvastatin in the treatment of hyperlipidemia]. Zhonghua yi xue za zhi 2017; 97:291-294. http://www.ncbi.nlm.nih.gov/pubmed/?term=28162160 

Women and elderly

  1. Clark D, Cho LS. Statin therapy in the frail elderly: A nuanced decision. Cleveland Clinic journal of medicine 2017; 84:143-145. http://www.ncbi.nlm.nih.gov/pubmed/?term=28198684
  2. McKibben RA, Al Rifai M, Mathews LM, Michos ED. Primary Prevention of Atherosclerotic Cardiovascular Disease in Women. Current cardiovascular risk reports 2016; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28149430
  3. Jones M, Tett S, Peeters GM et al. New-Onset Diabetes After Statin Exposure in Elderly Women: The Australian Longitudinal Study on Women's Health. Drugs Aging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28138911
  4. Sreter KB, Barisic B, Popovic-Grle S. Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome. International journal of clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28257284
  5. Bischoff-Ferrari HA, Fischer K, Orav EJ et al. Statin Use and 25-Hydroxyvitamin D Blood Level Response to Vitamin D Treatment of Older Adults. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28240766
  6. Elahi MM, Matata BM. Effects of maternal high-fat diet and statin treatment on bone marrow endothelial progenitor cells and cardiovascular risk factors in female mice offspring fed a similar diet. Nutrition 2017; 35:6-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=28241992
  7. Liu Z, Hao H, Yin C et al. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28177908
  8. McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28176447
  9. Balan A, Szaingurten-Solodkin I, Swissa SS et al. The effects of pravastatin on the normal human placenta: Lessons from ex-vivo models. PLoS One 2017; 12:e0172174. http://www.ncbi.nlm.nih.gov/pubmed/?term=28199380

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.

Cancella iscrizione | Unsubscribe | Inviato con MailUp